We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J Presents Positive Phase III Data on Psoriasis Candidate
Read MoreHide Full Article
Johnson & Johnson(JNJ - Free Report) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis. We remind investors that guselkumab is presently under review in the U.S. and EU for the plaque psoriasis indication.
This year so far, J&J’s share price is up 7.3%. This compares favorably with the 6.3% increase witnessed by the Zacks classified Large-Cap Pharma industry.
Coming back to the press release, data presented from the VOYAGE 2 trial (n=992) showed that significantly higher proportions of patients with moderate-to-severe plaque psoriasis treated with guselkumab achieved high rates of skin clearance compared to those receiving placebo. Around 70% of the patients receiving guselkumab achieved near complete skin clearance versus 2.4% on placebo.
The VOYAGE 2 trial also evaluated guselkumab versus AbbVie, Inc.’s (ABBV - Free Report) Humira. The study demonstrated the statistically significant efficacy of guselkumab compared to Humira at week 16, which was maintained through 24 weeks of treatment. Almost 46.8% of the patients treated with Humira achieved near complete skin clearance versus 70% for guselkumab. VOYAGE 2 data are consistent with data presented from the VOYAGE 1 study in October last year.
J&J also presented data from another phase III trial - NAVIGATE (n=871) - which evaluated the efficacy and safety of switching to guselkumab in moderate to severe plaque psoriasis patients who were not achieving clear or almost clear skin with J&J’s other plaque psoriasis medicine Stelara. Data from the study showed that patients who switched to guselkumab showed significantly greater improvements in skin clearance compared with patients who continued to receive Stelara.
Data from both the trials are being presented at the 2017 American Academy of Dermatology (AAD) annual meeting in Orlando this week.
Guselkumab, an anti-IL-23 human monoclonal antibody, was evaluated in three pivotal phase III studies – VOYAGE 1, VOYAGE 2 and NAVIGATE – for moderate-to-severe plaque psoriasis. A phase II trial evaluating guselkumab in moderate-to-severely active psoriatic arthritis is also ongoing.
Per the company’s press release, around 125 million people worldwide suffer from psoriasis, including 7.5 million Americans with their disease ranging from mild to severe and disabling. Hence, an approval of guselkumab will give the company access to a wide patient population in the U.S.
Shares of Celgene rose 18.6% in the past one year while earnings estimates for 2017 rose 1.2% in the past 60 days.
Shares of Summit Therapeutics rose 100% in the past one year while loss estimates for the current year ending Jan 2018 have narrowed by around 2% in the past 60 days.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
J&J Presents Positive Phase III Data on Psoriasis Candidate
Johnson & Johnson(JNJ - Free Report) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis. We remind investors that guselkumab is presently under review in the U.S. and EU for the plaque psoriasis indication.
This year so far, J&J’s share price is up 7.3%. This compares favorably with the 6.3% increase witnessed by the Zacks classified Large-Cap Pharma industry.
Coming back to the press release, data presented from the VOYAGE 2 trial (n=992) showed that significantly higher proportions of patients with moderate-to-severe plaque psoriasis treated with guselkumab achieved high rates of skin clearance compared to those receiving placebo. Around 70% of the patients receiving guselkumab achieved near complete skin clearance versus 2.4% on placebo.
The VOYAGE 2 trial also evaluated guselkumab versus AbbVie, Inc.’s (ABBV - Free Report) Humira. The study demonstrated the statistically significant efficacy of guselkumab compared to Humira at week 16, which was maintained through 24 weeks of treatment. Almost 46.8% of the patients treated with Humira achieved near complete skin clearance versus 70% for guselkumab. VOYAGE 2 data are consistent with data presented from the VOYAGE 1 study in October last year.
J&J also presented data from another phase III trial - NAVIGATE (n=871) - which evaluated the efficacy and safety of switching to guselkumab in moderate to severe plaque psoriasis patients who were not achieving clear or almost clear skin with J&J’s other plaque psoriasis medicine Stelara. Data from the study showed that patients who switched to guselkumab showed significantly greater improvements in skin clearance compared with patients who continued to receive Stelara.
Data from both the trials are being presented at the 2017 American Academy of Dermatology (AAD) annual meeting in Orlando this week.
Guselkumab, an anti-IL-23 human monoclonal antibody, was evaluated in three pivotal phase III studies – VOYAGE 1, VOYAGE 2 and NAVIGATE – for moderate-to-severe plaque psoriasis. A phase II trial evaluating guselkumab in moderate-to-severely active psoriatic arthritis is also ongoing.
Per the company’s press release, around 125 million people worldwide suffer from psoriasis, including 7.5 million Americans with their disease ranging from mild to severe and disabling. Hence, an approval of guselkumab will give the company access to a wide patient population in the U.S.
J&J carries a Zacks Rank #3 (Hold).
Stocks to Consider
Better-ranked stocks in the pharmaceutical sector are Celgene Corporation and Summit Therapeutics plc (SMMT - Free Report) , both with a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of Celgene rose 18.6% in the past one year while earnings estimates for 2017 rose 1.2% in the past 60 days.
Shares of Summit Therapeutics rose 100% in the past one year while loss estimates for the current year ending Jan 2018 have narrowed by around 2% in the past 60 days.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>